• Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization.
• LP-003 is the first innovative drug independently developed by LongBio Pharma to advance to BLA submission.

HANGZHOU, China, Sept. 14, 2026 /PRNewswire/ -- Altruist Biologics, a world-class contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK), congratulates its strategic partner LongBio Pharma (1779.HK) on the acceptance of its Biologics License Application (BLA) for LP-003 by the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis. This milestone marks LP-003 as the first anti-IgE biologic candidate in China to file a BLA for seasonal allergic rhinitis.

Allergic rhinitis is one of the most prevalent chronic diseases in China, with over 200 million patients suffering from symptoms such as nasal pruritus, sneezing, rhinorrhea and nasal congestion, which severely impairs work efficiency, sleep quality and daily life. Despite the proven clinical value of targeted anti-IgE therapy, such regimens have not yet been officially approved in China, leaving a large number of patients without optimal treatment options and creating significant unmet clinical needs.

LP-003, LongBio Pharma's flagship product, is a proprietary next-generation anti-IgE monoclonal antibody featuring an innovative sequence design. By binding to free IgE in the human body and blocking the interaction between IgE and the high-affinity IgE receptor (FcεRI), LP-003 is designed to interrupt the downstream allergic cascade reaction at its source, offering a targeted mechanism of action.

Altruist Biologics supported the program across the full CMC lifecycle, including process development, scale-up, GMP large-scale manufacturing and regulatory submission. Since the collaboration's onset, Altruist has leveraged its extensive biologics development and manufacturing expertise and internationally recognized quality systems to address key requirements spanning process robustness, production stability and data integrity. This integrated support enabled the program to progress efficiently through development and successfully reach BLA submission and acceptance.

Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, stated: "We are honored to enable LongBio Pharma to achieve the significant milestone of BLA acceptance for LP-003, which represents a critical advancement in treatments for allergic rhinitis in China. Developing therapies for such diseases is a long and challenging journey, requiring relentless joint efforts to bridge the gap between early-stage discovery and patients' access to medication. The successful NMPA acceptance of LongBio Pharma's BLA application not only reflects their dedication to allergic and autoimmune diseases but also exemplifies the value of Altruist Biologics' integrated CMC platform and regulatory support. We look forward to enabling the continued advancement of LP-003 toward commercialization, with the goal of providing an accessible and affordable treatment option for patients suffering from allergic diseases."

Dr. Liu Heng, Co-Founder, Chairman and CEO of LongBio Pharma commented: "The acceptance of LP-003's BLA marks an important stage in our continued efforts to advance innovative treatments for allergic diseases and bring new therapeutic options to patients in China. We are grateful to the Altruist Biologics team for their collaboration and technical expertise throughout the process, which has contributed to the successful advancement of LP-003 to this stage. We look forward to building on this strong partnership as we work closely with regulatory authorities to advance the review of LP-003 and ultimately bring this next-generation anti-IgE therapy to patients."

To date, Altruist Biologics has supported more than 100 biologics programs through IND-enabling and IND—as well as NDA and BLA—submission milestones. Through consistent execution and rigorous quality standards, the company continues to serve as a trusted long-term CDMO partner for biopharmaceutical companies in China and around the world.

For more information about Altruist Biologics' end-to-end service capabilities, please visit: www.altruistbio.com.

About LP-003

LP-003 is a next-generation anti-IgE monoclonal antibody with a novel sequence design. It targets and neutralizes free IgE to block IgE-mediated allergic pathways, covering a wide range of allergic disease indications. Multiple clinical trials of LP-003 are ongoing in China, and its IND application for peanut allergy has been approved by the U.S. FDA.

About LongBio Pharma

LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) is a clinical-stage innovative biopharmaceutical enterprise. The Company focuses on the independent research and development of novel biologics for allergic and autoimmune diseases, and has built a diversified product pipeline covering rhinology, dermatology, respiratory medicine, nephrology and other therapeutic areas. Committed to developing high-quality innovative biologic drugs, the Company strives to address unmet clinical medical needs in China.

About Altruist Biologics

Altruist Biologics is a reliable CDMO service provider and wholly owned subsidiary of Innovent Biologics, Inc. (1801.HK), focusing on the development, clinical, and commercial manufacturing of antibodies, fusion proteins, recombinant proteins, antibody drug conjugates, and other drugs. The company operates advanced cGMP facilities in Suzhou and Hangzhou, China, with a total production capacity of 232,000 liters, and continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility, safety and agility for clients. With over a decade of bioprocessing expertise, the company has supported the commercialization of 20 drugs and completed more than 2,000 commercial batches with a >99.8% success rate. Its track record includes 100 global regulatory filings with the FDA, EMA, NMPA, PMDA, and TGA as well as over 80 successful regulatory authority inspections across global markets. With over 1,400 employees, including leading experts and scientists spanning all areas of biologics production and innovation, Altruist is committed to supporting clients in developing affordable and high-quality biopharmaceuticals for the benefit of patients worldwide.

Media Contact:

Courtney Garcia

Director of Global Marketing & Communications

courtney.garcia@altruistbio.com

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/altruist-biologics-congratulates-partner-longbio-pharma-on-the-bla-acceptance-of-lp-003-by-the-china-nmpa-302876486.html

Beim Winterthurer Textilmaschinenhersteller Rieter kommt es zu einem abrupten Führungswechsel. CEO und Verwaltungsratspräsident Thomas Oetterli gibt beide Ämter per Ende Oktober ab. An die Spitze der Geschäftsführung rückt Anfang November der Branchenkenner Daniel Lippuner, während Carl Illi mit sofortiger Wirkung das Präsidium des Verwaltungsrats übernimmt. Rieter begründet den Schritt damit, dass nach der Umsetzung zentraler strategischer Projekte nun der Zeitpunkt gekommen sei, die Verantwortung in neue Hände zu legen.

Lippuner gilt als ausgewiesener Experte für Spinnmaschinen, Garnverarbeitung und Textilkomponenten. Er leitete früher den Textilmaschinenhersteller Saurer und zuvor den Bereich Oerlikon Textile Components. Zudem ist er Verwaltungsratspräsident und Miteigentümer von Heberlein Technology und damit weiterhin eng in der Chemiefaserindustrie verankert. Illi gehört dem Rieter-Verwaltungsrat seit 2017 an und wird vom Unternehmen ebenfalls als Textilexperte charakterisiert. Er soll das Präsidium mindestens bis zur nächsten Generalversammlung führen.

Oetterli, Jahrgang 1969 und früher Chef des Lift- und Rolltreppenherstellers Schindler, war im März 2023 zu Rieter geholt worden, um den bereits damals kriselnden Maschinenbauer zu stabilisieren. Noch im selben Jahr lancierte er das Performance-Programm «Next Level», das ein massives Kostensenkungs- und Restrukturierungspaket umfasst. Der Plan sah unter anderem vor, bis 2025 rund 1400 Vollzeitstellen vorwiegend in Deutschland, der Schweiz und weiteren europäischen Ländern abzubauen und Standorte zu konsolidieren. Parallel dazu übernahm Rieter im Februar die Textilmaschinensparte Barmag von OC Oerlikon, was mit einem deutlichen Anstieg der Verschuldung einherging.

Trotz dieser einschneidenden Massnahmen blieb die erhoffte Trendwende aus. Die Amtszeit Oetterlis war von einem ausserordentlich schwachen Marktumfeld mit anhaltender Nachfrageschwäche geprägt. 2024 hatte er zusätzlich das Präsidium des Verwaltungsrats übernommen – ein Doppelmandat, das den Aktionären ursprünglich als Übergangslösung zur konsequenten Umsetzung von «Next Level» verkauft worden war. Grösster Anteilseigner bei Rieter ist der Schweizer Industrielle Peter Spuhler mit einem Anteil von 33,1 Prozent; er sitzt ebenfalls im Verwaltungsrat. Der Führungswechsel in Winterthur folgt zeitlich auf eine ebenfalls angekündigte Neubesetzung an der Spitze von Stadler Rail, einem weiteren Unternehmen, an dem Spuhler die Kontrolle hält.